| http://www.w3.org/ns/prov#value | - This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the Oncotype DX is significant in changing treatment decisions in early stage breast cancer; the company's belief that the Oncotype DX cannot be predicted by other factors such as age or individual biomarkers; the compan
|
